EMERGENT BIOSOLUTIONS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.92 USD | -1.54% |
|
-5.88% | -20.00% |
| Sales 2024 * | 1.1B 91.69B | Sales 2025 * | 1.13B 93.96B | Capitalization | 101M 8.39B |
|---|---|---|---|---|---|
| Net income 2024 * | -83M -6.92B | Net income 2025 * | 66M 5.51B | EV / Sales 2024 * | 0.23 x |
| Net Debt 2024 * | 156M 12.99B | Net Debt 2025 * | 402M 33.5B | EV / Sales 2025 * | 0.45 x |
| P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
1.32
x | Employees | 1,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on Emergent BioSolutions Inc.
More recommendations
More press releases
More news
| 1 day | -1.54% | ||
| 1 week | -5.88% | ||
| Current month | -24.11% | ||
| 1 month | -24.11% | ||
| 3 months | +5.49% | ||
| 6 months | -4.00% | ||
| Current year | -20.00% |
1 week
1.90
2.36
1 month
1.822.61
Current year
1.423.73
1 year
1.4210.88
3 years
1.4268.03
5 years
1.42137.61
10 years
1.42137.61
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Papa
CEO | Chief Executive Officer | 68 | 21/02 |
Richard Lindahl
DFI | Director of Finance/CFO | 70 | 26/18/26 |
Kelly Warfield
CTO | Chief Tech/Sci/R&D Officer | - | 17/23/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 01/22/01 |
Marvin White
BRD | Director/Board Member | 62 | 01/10/01 |
Louis Sullivan
BRD | Director/Board Member | 90 | 01/05/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 27 M€ | -5.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.92 | -1.54% | 880,929 |
| 25/24/25 | 1.95 | -10.55% | 1,093,229 |
| 24/24/24 | 2.18 | -4.80% | 799,932 |
| 23/24/23 | 2.29 | +6.02% | 860,992 |
| 22/24/22 | 2.16 | +5.88% | 1,393,297 |
Delayed Quote Nyse, April 27, 2024 at 01:30 am IST
More quotes
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Sector
Pharmaceuticals
Calendar
01/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.92
USD
Average target price
5
USD
Spread / Average Target
+160.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 101M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- EBS Stock
